UNSPSC 51162020: Dyphylline/guaifenesin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162020 Dyphylline/guaifenesin is a Commodity code that nominally names a bronchodilator-expectorant combination, but recent state and local opportunities posted under this code show significant misalignment with the pharmaceutical classification. The two recent solicitations tagged to this code involve naloxone procurement and on-site pharmacy services delivery — neither of which falls within the dyphylline/guaifenesin drug category. The code appears to see minimal or misdirected activity, with state and local procurement offices using it to tag unrelated health services and opioid-antagonist supply contracts rather than the bronchodilator products the UNSPSC taxonomy intends. When the recent opportunities are reviewed on their actual substance, they do not represent genuine dyphylline/guaifenesin market activity.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, with a response deadline of July 26, 2023, and potential FEMA funding. Hall County, Georgia issued RFQ/P #47-010 in May 2026 to procure on-site pharmacy services at its family health center clinic in Gainesville, serving approximately 3,005 covered individuals across multiple insurance plan types, with responses due June 4, 2026, and contract award weighted 80% technical qualifications and 20% cost. Neither solicitation involves dyphylline/guaifenesin or other respiratory-category pharmaceuticals; the code's recent posting history suggests it does not currently reflect genuine state and local procurement activity in its nominal product category.